Literature DB >> 27093987

[The usage of Mayo staging system in Chinese patients with primary light chain amyloidosis].

Xufei Huang1, Jun Feng, Congli Zhang, Kaini Shen, Chunlan Zhang, Jian Sun, Zhuang Tian, Xinxin Cao, Lu Zhang, Daobin Zhou, Jian Li.   

Abstract

OBJECTIVE: To evaluate the usage of Mayo staging system in Chinese patients with primary light chain (LC) amyloidosis.
METHOD: Clinical data, treatment and outcome of 162 primary LC amyloidosis patients with Mayo Clinic staging in Peking Union Medical College Hospital from January 2009 to June 2015 were retrospectively analyzed.
RESULTS: The median age of 162 patients with Mayo Clinic 2004 stage was 57 (20-81) y, of them 62.3% were male. The number of patients with stage I to III were 44 (27.2%), 69 (42.6%), and 49 (30.2%), respectively. The median overall survival was not reached, 23 months and 12 months in patients with Mayo Clinic 2004 stage I, II, and III, respectively (P<0.001). Among 128 patients with Mayo Clinic 2012 stage, 48 patients (37.5%), 32 patients (25.0%), 32 patients (25.0%) and 16 patients (12.5%) were staged as Mayo Clinic 2012 stage 1 to 4, and the median OS was not reached, not reached, 13 months and 3 months, respectively (P<0.001).
CONCLUSION: Mayo Clinic staging systems had important prognostic value in patients with primary LC amyloidosis.

Entities:  

Mesh:

Year:  2016        PMID: 27093987     DOI: 10.3760/cma.j.issn.0253-2727.2016.04.005

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  2 in total

1.  [Clinical characteristics and prognostic analysis of monoclonal IgM-related AL amyloidosis].

Authors:  Y Y Mao; J Feng; Q Meng; K N Shen; X X Cao; D B Zhou; J Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

2.  [The consensus of the diagnosis and treatment of primary light chain amyloidosis in China (2016 version)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.